Docstoc
EXCLUSIVE OFFER FOR DOCSTOC USERS
Try the all-new QuickBooks Online for FREE.  No credit card required.

Leukemic Stem Cell Labeling System by Nucleostemin Prompter EGFP

Document Sample
Leukemic Stem Cell Labeling System by Nucleostemin Prompter EGFP Powered By Docstoc
					   FoxO3a is essential for survival of chronic myeloid leukemia-initiating cells



   Naka Kazuhito1, Noboru Motoyama2, Atsushi Hirao1
   (1 Division of Molecular Genetics, Cancer Research Institute, Kanazawa University, 2 Department of
   Geriatric Medicine, National Institute for Longevity Sciences, National Center for Gerontology and
   Geriatrics)



    Chronic myelogenous leukemia (CML) is attributed to a defined genetic abnormality, BCR-ABL, a
    constitutively active protein tyrosine kinase. Although the introduction of imatinib, a small molecule
Setup:
    inhibitor of ABL, represented a breakthrough in the treatment of CML, major part of patients treated
             Size: A4.                 Page therapy due to
    in chronic-phase CML are not offNumber: Single. resistance or intolerance. Recent studies have
             Orientation: Portrait. Margins: 25mm
                                                     of the direction.
    suggested that imatinib is a potent inhibitorin everyproduction of differentiated leukemic cells, but
             Characters per line: 40 characters.
    does not deplete leukemic stem cells. To date, therapeutics that can eradicate CML-initiating cells,
             Lines per page: 38 lines.
             Character’s font: Times New Roman. Character’s size: 12 these
    however, have remained under investigation. To overcomepoints. clinical problems, we here
    evaluated molecular mechanisms on survival of the CML-initiating cells. We first generated a mouse
             Space: Single line spacing
Lines order:
    CML model by using retroviral induction of BCR-ABL-ires-GFP gene into mouse immature
     Title: bold , cells, and the cells
   hematopoietic aligned to the left. were subsequently transplanted into irradiated recipient mice. The
     Two blank lines.
   transplantation experiments showed that CML-initiating cells were highly enriched in
     Researchers’ names: aligned to the left with the presenter’s name underlined.
   c-Kit+Lin-Sca-1+ (KLS+) population in BCR-ABL+ CML cells, as previously described.
     Affiliation: aligned to the left and enclosed between brackets.
   Unexpectedly, phosphorylation level of Akt in KLS+ population as CML-initiating cells appeared to
     Two blank lines.
   be lower than that in non- the left cells, KLS- cells, despite it is widely believed that BCR-ABL
     Abstract text :aligned to initiating
   induces activation of Akt signal. Since Forkhead O (Foxo) transcription factors, which are important
   downstream targets of PI3K-Akt signaling, are essential for the maintenance of self-renewal capacity
   of normal HSCs, we focused on analysis of Foxo3a in CML. Consistent with Akt phosphorylation
   status, we found that approximately 40% of CML KLS+ showed nuclear localization of Foxo3a,
   whereas majority of KLS- cells showed the cytoplasmic localization, suggesting that Foxo3a is
   activated via Akt inactivation in the rare CML-initiating cells, but not in majority of CML cells.
   Serial transplantation experiments for CML-initiating cells originated from Foxo3a-deficient mice
   and littermate wild-type mice indicated that Foxo3a-deficiency attenuated the ability of
   CML-initiating cells to develop leukemia at third round transplantation experiments. Number of
   Annexin-V+ cells was higher in the Foxo3a-deficient CML-initiating cells than those seen in
   wild-type CML-initiating cells in vivo. Furthermore, deficiency of Foxo3a led to enhanced efficiency
   in elimination of CML-initiating cells in combination with imatinib treatment. These results
   demonstrate a critical role of Foxo pathway in survival of drug-resistant CML-initiating cells, and
   provide a novel therapeutics approach for CML patients by suppression of FOXO signaling.

				
DOCUMENT INFO